FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226424942> ?p ?o ?g. }

• W4226424942 abstract "Canine soft tissue sarcoma (STS) has served as a preclinical model for radiation, hyperthermia, experimental therapeutics, and tumor microenvironmental research for decades. Stereotactic body radiotherapy (SBRT) demonstrates promising results for the control of various tumors in human and veterinary medicine; however, there is limited clinical data for the management of STS with SBRT. In this retrospective study, we aimed to define overall efficacy and toxicity of SBRT for the treatment of macroscopic canine STS to establish this preclinical model for comparative oncology research. Fifty-two canine patients met inclusion criteria. Total radiation dose prescribed ranged from 20-50 Gy delivered in 1-5 fractions. Median progression-free survival time (PFST) was 173 days and overall survival time (OST) 228 days. Best overall response was evaluable in 46 patients, with 30.4% responding to treatment (complete response n = 3; partial response n = 11). For responders, OST significantly increased to 475 days vs. 201 days (P = 0.009). Prognostic factors identified by multivariable Cox regressions included size of tumor and metastasis at presentation. Dogs were 3× more likely to progress (P = 0.009) or 3.5× more likely to experience death (P = 0.003) at all times of follow up if they presented with metastatic disease. Similarly, every 100-cc increase in tumor volume resulted in a 5% increase in the risk of progression (P = 0.002) and death (P = 0.001) at all times of follow up. Overall, 30.8% of patients developed acute toxicities, 7.7% grade 3; 28.8% of patients developed late toxicities, 11.5% grade 3. Increased dose administered to the skin significantly affected toxicity development. SBRT serves as a viable treatment option to provide local tumor control for canine macroscopic STS, particularly those with early-stage disease and smaller tumors. The results of this study will help to define patient inclusion criteria and to set dose limits for preclinical canine STS trials involving SBRT." @default.
• W4226424942 created "2022-05-05" @default.
• W4226424942 creator A5016795218 @default.
• W4226424942 creator A5022248464 @default.
• W4226424942 creator A5033791088 @default.
• W4226424942 creator A5034184736 @default.
• W4226424942 creator A5066001219 @default.
• W4226424942 creator A5076429572 @default.
• W4226424942 creator A5080166325 @default.
• W4226424942 creator A5085053907 @default.
• W4226424942 creator A5085581902 @default.
• W4226424942 date "2021-09-02" @default.
• W4226424942 modified "2023-10-18" @default.
• W4226424942 title "Response of Canine Soft Tissue Sarcoma to Stereotactic Body Radiotherapy" @default.
• W4226424942 cites W138275311 @default.
• W4226424942 cites W1662908470 @default.
• W4226424942 cites W1761376684 @default.
• W4226424942 cites W1965110058 @default.
• W4226424942 cites W1970687677 @default.
• W4226424942 cites W1971747664 @default.
• W4226424942 cites W1983274306 @default.
• W4226424942 cites W2001143955 @default.
• W4226424942 cites W2002104918 @default.
• W4226424942 cites W2009414609 @default.
• W4226424942 cites W2015535014 @default.
• W4226424942 cites W2018826865 @default.
• W4226424942 cites W2021415374 @default.
• W4226424942 cites W2027501539 @default.
• W4226424942 cites W2032252262 @default.
• W4226424942 cites W2036558320 @default.
• W4226424942 cites W2038323798 @default.
• W4226424942 cites W2054200094 @default.
• W4226424942 cites W2054384148 @default.
• W4226424942 cites W2056574005 @default.
• W4226424942 cites W2060827797 @default.
• W4226424942 cites W2064754413 @default.
• W4226424942 cites W2068353013 @default.
• W4226424942 cites W2080377583 @default.
• W4226424942 cites W2088021312 @default.
• W4226424942 cites W2095971807 @default.
• W4226424942 cites W2104590368 @default.
• W4226424942 cites W2109032601 @default.
• W4226424942 cites W2109140028 @default.
• W4226424942 cites W2119032282 @default.
• W4226424942 cites W2125073739 @default.
• W4226424942 cites W2125590208 @default.
• W4226424942 cites W2126683897 @default.
• W4226424942 cites W2127428399 @default.
• W4226424942 cites W2130658267 @default.
• W4226424942 cites W2137506570 @default.
• W4226424942 cites W2145874471 @default.
• W4226424942 cites W2154353737 @default.
• W4226424942 cites W2155344217 @default.
• W4226424942 cites W2180665796 @default.
• W4226424942 cites W2219119728 @default.
• W4226424942 cites W2295993263 @default.
• W4226424942 cites W2298272175 @default.
• W4226424942 cites W2299680762 @default.
• W4226424942 cites W2342672703 @default.
• W4226424942 cites W2412862678 @default.
• W4226424942 cites W2494461917 @default.
• W4226424942 cites W2522353816 @default.
• W4226424942 cites W2566074209 @default.
• W4226424942 cites W2585010490 @default.
• W4226424942 cites W2751350166 @default.
• W4226424942 cites W2769044758 @default.
• W4226424942 cites W2789659603 @default.
• W4226424942 cites W2793692268 @default.
• W4226424942 cites W2796052679 @default.
• W4226424942 cites W2801821552 @default.
• W4226424942 cites W2808624051 @default.
• W4226424942 cites W2812448774 @default.
• W4226424942 cites W2889646458 @default.
• W4226424942 cites W2898695706 @default.
• W4226424942 cites W2909649426 @default.
• W4226424942 cites W2929813488 @default.
• W4226424942 cites W2969361214 @default.
• W4226424942 cites W2985271011 @default.
• W4226424942 cites W2987697371 @default.
• W4226424942 cites W2995748999 @default.
• W4226424942 cites W2999814752 @default.
• W4226424942 cites W3014356142 @default.
• W4226424942 cites W3081892691 @default.
• W4226424942 doi "https://doi.org/10.1667/rade-20-00271.1" @default.
• W4226424942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34473832" @default.
• W4226424942 hasPublicationYear "2021" @default.
• W4226424942 type Work @default.
• W4226424942 citedByCount "4" @default.
• W4226424942 countsByYear W42264249422022 @default.
• W4226424942 countsByYear W42264249422023 @default.
• W4226424942 crossrefType "journal-article" @default.
• W4226424942 hasAuthorship W4226424942A5016795218 @default.
• W4226424942 hasAuthorship W4226424942A5022248464 @default.
• W4226424942 hasAuthorship W4226424942A5033791088 @default.
• W4226424942 hasAuthorship W4226424942A5034184736 @default.
• W4226424942 hasAuthorship W4226424942A5066001219 @default.
• W4226424942 hasAuthorship W4226424942A5076429572 @default.
• W4226424942 hasAuthorship W4226424942A5080166325 @default.
• W4226424942 hasAuthorship W4226424942A5085053907 @default.
• W4226424942 hasAuthorship W4226424942A5085581902 @default.

• next